Cargando…

Pharmacokinetics and Safety of Single and Multiple Doses of Peficitinib (ASP015K) in Healthy Chinese Subjects

OBJECTIVE: To investigate the pharmacokinetics and safety of peficitinib (Janus kinase inhibitor for the treatment of rheumatoid arthritis) in healthy Chinese subjects following single and multiple doses. METHODS: This open-label, randomized study was conducted at one site in China. Subjects receive...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gao, Xin, He, Xuemei, Oshima, Hiroyuki, Miyatake, Daisuke, Otsuka, Yukio, Kato, Kota, Cai, Chunxiao, Wojtkowski, Tomasz, Song, Nan, Kaneko, Yuichiro, Shi, Aixin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9109889/ https://www.ncbi.nlm.nih.gov/pubmed/35586186 http://dx.doi.org/10.2147/DDDT.S359501

Ejemplares similares

Pharmacokinetics, Pharmacodynamics, and Safety of Peficitinib (ASP015K) in Healthy Male Caucasian and Japanese Subjects
por: Shibata, Mai, et al.
Publicado: (2020)

Pharmacokinetics and Safety of a Single Oral Dose of Peficitinib (ASP015K) in Japanese Subjects with Normal and Impaired Renal Function
por: Miyatake, Daisuke, et al.
Publicado: (2019)

Pharmacokinetics and Safety of a Single Oral Dose of Peficitinib (ASP015K) in Japanese Subjects With Normal and Impaired Hepatic Function
por: Miyatake, Daisuke, et al.
Publicado: (2019)

Patient- and physician-reported outcomes from two phase 3 randomized studies (RAJ3 and RAJ4) of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis
por: Tanaka, Yoshiya, et al.
Publicado: (2021)

Safety and Effectiveness of Peficitinib (ASP015K) in Patients with Rheumatoid Arthritis: Final Results (32 Months of Mean Peficitinib Treatment) From a Long-Term, Open-Label Extension Study in Japan, Korea, and Taiwan
por: Takeuchi, Tsutomu, et al.
Publicado: (2021)

Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan
por: Takeuchi, Tsutomu, et al.
Publicado: (2020)

Correction to: Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan
por: Takeuchi, Tsutomu, et al.
Publicado: (2020)

Population pharmacokinetic analysis of peficitinib in patients with rheumatoid arthritis
por: Toyoshima, Junko, et al.
Publicado: (2020)

Investigation of Potential Drug–Drug Interactions between Peficitinib (ASP015K) and Methotrexate in Patients with Rheumatoid Arthritis
por: Zhu, Tong, et al.
Publicado: (2020)

The Bioequivalence of Two Peficitinib Formulations, and the Effect of Food on the Pharmacokinetics of Peficitinib: Two‐Way Crossover Studies of a Single Dose of 150 mg Peficitinib in Healthy Volunteers
por: Shibata, Mai, et al.
Publicado: (2020)

Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan
por: Takeuchi, Tsutomu, et al.
Publicado: (2019)

Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3)
por: Tanaka, Yoshiya, et al.
Publicado: (2019)

Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study
por: Takeuchi, Tsutomu, et al.
Publicado: (2016)

Exposure–response modeling of peficitinib efficacy in patients with rheumatoid arthritis
por: Toyoshima, Junko, et al.
Publicado: (2021)

Comparison of the Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Healthy Japanese and Caucasian Subjects
por: Oshima, Hiroyuki, et al.
Publicado: (2015)

A drug–drug interaction study to evaluate the impact of peficitinib on OCT1- and MATE1-mediated transport of metformin in healthy volunteers
por: Shibata, Mai, et al.
Publicado: (2020)

Comparative Efficacy and Safety of Peficitinib Versus Tofacitinib and Baricitinib for Treatment of Rheumatoid Arthritis: A Systematic Review and Network Meta-Analysis
por: Tanaka, Yoshiya, et al.
Publicado: (2021)

Targeting Activated Synovial Fibroblasts in Rheumatoid Arthritis by Peficitinib
por: Diller, Magnus, et al.
Publicado: (2019)

Efficacy of peficitinib in two patients with rheumatoid arthritis on maintenance hemodialysis
por: Nishimura, Akito, et al.
Publicado: (2022)

Pharmacokinetic Evaluation of the Interactions of Amenamevir (ASP2151) with Ketoconazole, Rifampicin, Midazolam, and Warfarin in Healthy Adults
por: Kusawake, Tomohiro, et al.
Publicado: (2017)

Successful peficitinib addition on anti-MDA5 antibody-positive dermatomyositis refractory to triple therapy and glucocorticoid reduction
por: Oba, Yuki, et al.
Publicado: (2022)

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Sotagliflozin After Multiple Ascending Doses in Chinese Healthy Subjects
por: He, Xuemei, et al.
Publicado: (2022)

Single‐ and multiple‐dose safety, tolerability, pharmacokinetic, and pharmacodynamic profiles of ASP0367, or bocidelpar sulfate, a novel modulator of peroxisome proliferator‐activated receptor delta in healthy adults: Results from a phase 1 study
por: Ito, Mototsugu, et al.
Publicado: (2021)

In vitro pharmacological effects of peficitinib on lymphocyte activation: a potential treatment for systemic sclerosis with JAK inhibitors
por: Kitanaga, Yukihiro, et al.
Publicado: (2020)

Peficitinib Inhibits the Chemotactic Activity of Monocytes via Proinflammatory Cytokine Production in Rheumatoid Arthritis Fibroblast-Like Synoviocytes
por: Ikari, Yuzo, et al.
Publicado: (2019)

Pharmacokinetics, Safety and Tolerability of Once-Weekly Subcutaneous Semaglutide in Healthy Chinese Subjects: A Double-Blind, Phase 1, Randomized Controlled Trial
por: Shi, Aixin, et al.
Publicado: (2020)

Antibacterial mechanism of the Asp-Asp-Asp-Tyr peptide
por: Zhuang, Shanshan, et al.
Publicado: (2022)

2535. Physiological-based pharmacokinetic analysis of drug–drug interactions between isavuconazole and vincristine in pediatric subjects
por: Choules, Mary P, et al.
Publicado: (2023)

Identification of the Lomofungin Biosynthesis Gene Cluster and Associated Flavin-Dependent Monooxygenase Gene in Streptomyces lomondensis S015
por: Zhang, Chunxiao, et al.
Publicado: (2015)

Jumping from ASP to ASP.NET
por: Parsons, Doug
Publicado: (2008)

Two-Year Safety and Effectiveness of Peficitinib in Moderate-To-Severe Rheumatoid Arthritis: A Phase IIb, Open-Label Extension Study
por: Genovese, Mark C., et al.
Publicado: (2019)

The Influence of Hepatic and Renal Impairment on the Pharmacokinetics of a Treatment for Herpes Zoster, Amenamevir (ASP2151): Phase 1, Open-Label, Single-Dose, Parallel-Group Studies
por: Kusawake, Tomohiro, et al.
Publicado: (2017)

Safety, Pharmacokinetics, and Pharmacodynamics of ASP3662, a Novel 11β‐Hydroxysteroid Dehydrogenase Type 1 Inhibitor, in Healthy Young and Elderly Subjects
por: Bellaire, Susan, et al.
Publicado: (2019)

ASP
por: Berardi, Nick, et al.
Publicado: (2009)

ASP
por: Varallo, Vincent
Publicado: (2009)

ASP
por: Love, Chris
Publicado: (2009)

ODP015 "Malignant" Hypertension in an Older Male
por: Naha, Sowjanya, et al.
Publicado: (2022)

DRAFT ATLAS ATRECON manual (Version 0.015)
por: Offline Software Group
Publicado: (1994)

The ATLAS Level-1 Central Trigger System 015
por: Borrego-Amaral, P, et al.
Publicado: (2004)

Optimization of the Fermentation Process of Actinomycete Strain Hhs.015(T)
por: Wang, Xinxuan, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_5nmir6q5296dcl34235jcedira